Physician profile
Celine Gisbert
NPI 1831216969
$1,350.84
in general payments reported to CMS, 2019-2025
16 companies · $103 in 2025
The $103 reported for 2025 was less than what a typical Obesity Medicine (Family Medicine) provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $110 · 2021: $107 · 2022: $187 · 2023: $21.85 · 2024: $99.61 · 2025: $103.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $224.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $789.42 | 2019-2025 | Wegovy |
| Lilly USA, LLC | $110.62 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $67.22 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.40 | 2019 | |
| Pfizer INC. | $48.65 | 2019 | |
| Glaxosmithkline, LLC. | $41.77 | 2019 | |
| Abbott Laboratories | $38.51 | 2022-2023 | Freestyle Libre 3 |
| Shire North American Group INC | $32.35 | 2019 | |
| Amgen INC. | $26.88 | 2019 | |
| Allergan, INC. | $26.73 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $24.41 | 2019 | |
| Endo Pharmaceuticals INC. | $24.15 | 2019 | |
| Kvk-Tech, INC. | $21.99 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $16.94 | 2019 | |
| Merck Sharp & Dohme LLC | $11.91 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celine Gisbert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.